From neurodegeneration to neurohomeostasis: the role of ubiquitin
- PMID:12792671
- DOI: 10.1358/dnp.2003.16.2.829327
From neurodegeneration to neurohomeostasis: the role of ubiquitin
Abstract
Several years ago ubiquitin immunocytochemistry first demonstrated that ubiquitin protein conjugates are present in intraneuronal inclusions in all the major human chronic neurodegenerative diseases, as well as in inclusions in cerebellar astrocytomas and in hepatocytes in alcoholic liver disease. Unexpectedly, further studies showed that Lewy bodies are present in the cortex. Lewy bodies were originally described in the brain stem and are pathogonomic in the neuropathological diagnosis of Parkinson's disease. A balanced interpretation of further elegant experimental approaches, including transgenesis, suggests that the formation of intraneuronal inclusions is cytoprotective. Putative oligomeric proaggregates (prefibrillar entities) of cellular proteins inhibit the 26S proteasome and promote apoptosis. In the last few years a clutch of distinct experimental approaches have focused on the roles of ubiquitin-related processes in the development of the nervous system and neurohomeostasis. It is now clear that the ubiquitin/proteasome system (UPP) has a pivotal role in synaptogenesis, the formation of neuromuscular junctions and neurotransmitter receptor function. The inhibitory GABA(A) receptor, alpha1 glycine receptor, beta(2)-adrenergic receptor and arrestin, opiate receptors and the excitatory metabotropic glutamate receptor (mGluR1alpha) are regulated by the UPP. It is also increasingly clear that the regulation of long-term synaptic plasticity, and therefore memory, is dependent on both protein synthesis and protein degradation. Therefore, for the first time we have the opportunity to dissect the substrate of memory and the basis of cognitive decline in aging and in chronic neurodegenerative disease. Clearly, further understanding will provide a platform for novel drug development to treat chronic neurodegenerative diseases, including Alzheimer- and Parkinson-related conditions, and possibly psychiatric disorders.
(c) 2003 Prous Science. All rights reserved.
Similar articles
- Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly.Ii K, Ito H, Tanaka K, Hirano A.Ii K, et al.J Neuropathol Exp Neurol. 1997 Feb;56(2):125-31. doi: 10.1097/00005072-199702000-00002.J Neuropathol Exp Neurol. 1997.PMID:9034365
- Failure of the ubiquitin-proteasome system in Parkinson's disease.McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P.McNaught KS, et al.Nat Rev Neurosci. 2001 Aug;2(8):589-94. doi: 10.1038/35086067.Nat Rev Neurosci. 2001.PMID:11484002Review.No abstract available.
- UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.Ardley HC, Scott GB, Rose SA, Tan NG, Robinson PA.Ardley HC, et al.J Neurochem. 2004 Jul;90(2):379-91. doi: 10.1111/j.1471-4159.2004.02485.x.J Neurochem. 2004.PMID:15228595
- The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.Chung KK, Dawson VL, Dawson TM.Chung KK, et al.Trends Neurosci. 2001 Nov;24(11 Suppl):S7-14. doi: 10.1016/s0166-2236(00)01998-6.Trends Neurosci. 2001.PMID:11881748Review.
- Damage control--a possible non-proteolytic role for ubiquitin in limiting neurodegeneration.Gray DA.Gray DA.Neuropathol Appl Neurobiol. 2001 Apr;27(2):89-94. doi: 10.1046/j.1365-2990.2001.00321.x.Neuropathol Appl Neurobiol. 2001.PMID:11437989Review.
Cited by
- Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.Huang Q, Figueiredo-Pereira ME.Huang Q, et al.Apoptosis. 2010 Nov;15(11):1292-311. doi: 10.1007/s10495-010-0466-z.Apoptosis. 2010.PMID:20131003Free PMC article.Review.
- Natural toxins implicated in the development of Parkinson's disease.Salama M, Arias-Carrión O.Salama M, et al.Ther Adv Neurol Disord. 2011 Nov;4(6):361-73. doi: 10.1177/1756285611413004.Ther Adv Neurol Disord. 2011.PMID:22164190Free PMC article.
- Case Report: Contiguous Xq22.3 Deletion Associated with ATS-ID Syndrome: From Genotype to Further Delineation of the Phenotype.Smetana J, Vallova V, Wayhelova M, Hladilkova E, Filkova H, Horinova V, Broz P, Mikulasova A, Gaillyova R, Kuglík P.Smetana J, et al.Front Genet. 2021 Oct 29;12:750110. doi: 10.3389/fgene.2021.750110. eCollection 2021.Front Genet. 2021.PMID:34777475Free PMC article.
- Molecular and cellular pathways contributing to brain aging.Zia A, Pourbagher-Shahri AM, Farkhondeh T, Samarghandian S.Zia A, et al.Behav Brain Funct. 2021 Jun 12;17(1):6. doi: 10.1186/s12993-021-00179-9.Behav Brain Funct. 2021.PMID:34118939Free PMC article.Review.
- Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation.Marquez-Lona EM, Torres-Machorro AL, Gonzales FR, Pillus L, Patrick GN.Marquez-Lona EM, et al.PLoS One. 2017 Jun 29;12(6):e0179893. doi: 10.1371/journal.pone.0179893. eCollection 2017.PLoS One. 2017.PMID:28662109Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Medical